Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial cancer. Monoclonal antibodies (mAbs) against either PD-1 or PD-L1 are active agents for these patients; however, their use may be complicated by unpredictable immune-related adverse events (irAEs), including immune-related pneumonitis (IRP). We carried out a retrospective multi-institutional statistical analysis to investigate clinical and biological parameters correlated with IRP rate on a cohort of 256 patients who received real-world treatment with PD-1/PD-L1 blocking mAbs. An independent radiological review board detected IRP in 29 patients. We did not find statistical IRP rate correlation with gender, tumor type, specific PD-1 or PD-L1 blocking mAbs, radiation therapy, inflammatory profile, or different irAEs. A higher IRP risk was detected only in mNSCLC patients who received metronomic chemotherapy +/− bevacizumab compared with other treatments prior PD-1/PD-L1 blockade. Moreover, we detected a strong correlation among the IRP rate and germinal expression of HLA-B*35 and DRB1*11, alleles associated to autoimmune diseases. Our findings may have relevant implications in predicting the IRP rate in mNSCLC patients receiving PD-1/PD-L1 blockade and need to be validated on a larger patient series.

Cardiac metastases (CMs) are more common than primary cardiac tumors, with autopsy studies reporting incidence rates between 2.3% and 18.3%. Their increasing detection is largely attributed to advances in cancer treatments, which have extended patient survival. CMs may present with diverse clinical manifestations depending on their size, location, and extent of infiltration, although they often remain asymptomatic and are identified only postmortem. Sometimes, they are incidentally discovered during tumor staging or follow-up evaluations. This review explores the incidence, pathophysiology, clinical features, and potential complications of CMs, focusing on their prevalence and characteristics. It highlights the importance of early detection and optimized management strategies to address this growing clinical concern. Further research is essential to elucidate the mechanisms driving CMs and develop effective therapeutic interventions.